James Kihara - 17 Nov 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: Principal Accounting Officer
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 17 Nov 2023
Net transactions value: -$44,940
Form type: 4
Filing time: 21 Nov 2023, 18:00:14 UTC
Previous filing: 19 Sep 2023
Next filing: 15 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+1,982	+18%		13,028	17 Nov 2023	Direct	F1, F2
transaction	ACAD	Common Stock	Options Exercise		+1,982	+15%		15,010	17 Nov 2023	Direct	F1
transaction	ACAD	Common Stock	Sale	$44,940	-1,985	-13%	$22.64	13,025	20 Nov 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-1,982	-20%	$0.000000	7,931	17 Nov 2023	Common Stock	1,982		Direct	F1, F5
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-1,982	-20%	$0.000000	7,931	17 Nov 2023	Common Stock	1,982		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 268 shares of the Issuer's common stock acquired by the reporting person on November 15, 2023 pursuant to an employee stock purchase program.
F3	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.615 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
F6	The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.